Hospital laboratory experience with SARS-CoV-2 (COVID-19) molecular assay sample pooling method in New York City
| Autor: | Iskender Sinan Genco, Oana Vele, Dennise Otero Espinal, Scott Duong, Jeffrey Pacheco, Kevin P. Williams |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Sample (material) Pooling Medical laboratory Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Transport medium Pandemic medicine Humans GeneXpert MTB/RIF business.industry SARS-CoV-2 COVID-19 General Medicine Viral Load medicine.disease Laboratories Hospital 030104 developmental biology Molecular Diagnostic Techniques 030220 oncology & carcinogenesis COVID-19 Nucleic Acid Testing New York City Medical emergency business |
| Zdroj: | Journal of clinical pathology. 75(1) |
| ISSN: | 1472-4146 |
| Popis: | The ongoing SARS-CoV-2 (COVID-19) pandemic has been a huge challenge for healthcare systems worldwide. Laboratories have been confronted with rapidly increasing testing demands that exceed testing capacity. Regions with a low SARS-CoV-2 molecular assay positivity rate are looking for ways to increase testing capacity and prevent a second wave while returning to ‘normal’ life. One aspect of this process is to reopen non-COVID-19 related medical services that were shut down due to SARS-CoV-2 transmission risk. Sample pooling method has been used for mass testing of several infectious diseases for decades and is currently proposed as a new strategy to increase COVID-19 testing capacity in low-risk regions.1–5 New York State Department of Health (NYSDOH) requires patients to be tested for COVID-19 using a molecular assay for detection of SARS-CoV-2 RNA before medical procedures. While the number of medical procedures were rapidly increasing at our hospital, the supply of SARS-CoV-2 molecular assay reagents has been insufficient and inconsistent. To meet the need of testing before medical procedures in a timely manner and prevent possible delays in patient care, Lenox Hill Hospital laboratory implemented the sample pooling method for patient testing. We, herein, report our 6-week experience with pool testing for COVID-19. In the beginning of July 2020, we validated the pooling testing method for COVID-19 using the Cepheid Xpert Xpress SARS-2 CoV-2 (EUA) cartridges on GeneXpert System (Cepheid, Sunnyvale, California, USA) by using the recent guidelines published by the Food and Drug Administration and NYSDOH.6 7 The SARS-CoV-2 positivity rate at Lenox Hill Hospital of Northwell Health was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|